Ponatinib
Epithelial Tumor
University Health Network, TorontoSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
24 Active assets in the Epithelial Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sorafenib Shandong Cancer Hospital and Institute | Phase 3 | BB |
Catumaxomab Neovii Biotech | Phase 2/3 | B |
Pembrolizumab Sheba Medical Center | Phase 2 | B |
Enadenotucirev Akamis Bio | Phase 1/2 | B |
Linifanib Abbott | Phase 3 | B |
View all 36 →
Same molecule, other indications
Ponatinib is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
65 / 100
View asset →blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
BB
Indicative ·
65 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →